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Mass and top-down analyses of 150-kDa monoclonal immunoglobulin gamma (IgG) antibod-
ies were performed on an Orbitrap analyzer. Three different sample delivery methods were
tested including (1) infusion of an off-line desalted IgG sample using nano-electrospray; (2)
on-line desalting followed by a step elution with a high percentage of organic solvent; and (3)
reversed-phase HPLC separation and on-line mass and top-down analyses of disulfide
isoforms of an IgG2 antibody. The accuracy of mass measurements of intact antibody was
within 2 Da (15 ppm). The glycoforms of intact IgG antibodies separated by 162 Da were
baseline resolved. In-source fragmentation of the intact antibodies produced mainly 115
residue fragments including N-terminal variable domains of heavy and light chains. The
sequence coverage (the number of cleavages) was greatly increased after reduction of
disulfide bonds and HPLC/MS/MS analysis of light and heavy chains using collision-
induced dissociation in the ion trap of the LTQ-Orbitrap. This is an attractive alternative
to peptide mapping for characterization and monitoring of post-translational modifica-
tions attributed to minimal sample preparation, high speed of the mass/top-down
analysis, and relatively minor method-induced sample modifications. (J Am Soc Mass
Spectrom 2009, 20, 1415–1424) © 2009 Published by Elsevier Inc. on behalf of American
Society for Mass SpectrometryBecause of their predictable properties, controlledfunction and long circulation lifetime, monoclo-nal human immunoglobulin gamma (IgG) anti-
bodies have emerged as a popular therapeutic modality
[1, 2]. This has resulted in a strong need for a high-
throughput methods for analysis of different antibody
drug candidates. Mass spectrometry has become one of
the most powerful techniques for the structural charac-
terization of monoclonal antibodies (mAbs) [3]. Tradi-
tionally, structural characterization of mAbs has been
performed by a “bottom-up” approach after first digest-
ing them to peptides [4–6]. Unfortunately, enzymatic
digestion is a laborious, time-consuming process and it
often introduces artificial modifications, such as cycliza-
tion of N-terminal glutamine and deamidation [5, 7].
Alternatively, protein molecular mass analysis is rela-
tively fast, does not require lengthy sample preparation,
and induces fewer, if any, modifications [8] compared
with the peptide mapping [5, 7]. Analysis of intact
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doi:10.1016/j.jasms.2009.03.020monoclonal IgG antibodies and their large domains has
been reported for matrix-assisted laser desorption/
ionization (MALDI) and electrospray ionization (ESI)
sources and almost all mass analyzers including
MALDI-time of flight (TOF) [9–11], ESI quadrupole (Q)
[4, 12–14], ion trap [15], orthogonal TOF [8, 11, 16, 17],
and the LTQ-Orbitrap during direct infusion [18]. Al-
though a mass change in a population of mAbs can be
used to monitor post-translational modifications [8], it
cannot reveal the site of modification. For that purpose,
fragmentation of intact proteins, also known as “top-
down” mass spectrometry, has been developed during
the past decade [19–25] using mainly high-resolving
power Fourier transform ion cyclotron resonance (FT-
ICR) mass spectrometers. Combination of intact protein
mass measurement and top-down fragmentation anal-
ysis provided useful information about sites of post-
translational modifications (PTMs) in several studies
including oxidation of viral prolyl-4-hydroxylase [20]
and deamidation of ribonuclease A [23], to name a few.
Discovery of the Orbitrap analyzer [26] and its first
commercialization as a hybrid linear quadrupole ion
trap–Orbitrap mass spectrometer (LTQ Orbitrap, Thermo
Published online March 28, 2009
ass Spectrometry. Received December 28, 2008
Revised March 18, 2009
Accepted March 20, 2009
1416 BONDARENKO ET AL. J Am Soc Mass Spectrom 2009, 20, 1415–1424Scientific, Bremen, Germany) provided many laborato-
ries with the opportunity to achieve high mass resolu-
tion without a superconducting magnet and its special
and expensive maintenance. The LTQ-Orbitrap was
used for top-down analysis of intact monoclonal IgG
antibodies [27] and their light and heavy chains [18]
during direct infusion as well as on-line with HPLC [3].
In addition, top-down (tandem mass spectroscopy,
MS/MS) analysis of antibody chains was performed
using a q-TOF mass spectrometer during direct infusion
[28], and on-line with HPLC using in-source N-terminal
fragmentation on an orthogonal-TOF instrument [29].
During production and formulation of a mAb, it is
important to separate and quantify all isoforms of
therapeutic antibody with different PTMs to further
identify the sites of the modifications and their impact
on potency, stability, and other critical attributes of the
therapeutic molecules. To avoid time-consuming and
costly fractionation and fraction collection and subse-
quent peptide mapping of the separated isoforms, it is
very attractive to separate the intact protein isoforms by
liquid chromatography and then perform on-line mass
and top-down analyses to determine the sites of modi-
fications and their abundances in one short assay. In the
previous work by Zhang and Shah the modifications
inside the variable domains of antibodies were success-
fully characterized by a simple top-down method on
the Orbitrap analyzer [27]. However, mass measure-
ment of the intact antibodies was usually performed on
a separate TOF analyzer, limiting the throughput of the
analysis. Therefore, it was desirable to combine the
mass measurement and the top-down fragmentation
analysis of a mAb in one automated procedure. This
report describes a step toward implementation of such
analysis of human monoclonal antibodies and their
large subunits (light and heavy chains after reduction of
disulfide bonds) using the LTQ Orbitrap. We report
mass measurements and top-down fragmentation anal-
yses of intact and reduced IgG antibodies on the LTQ-
Orbitrap connected to reversed-phase HPLC.
Experimental
Materials
The recombinant monoclonal IgG1 and IgG2 antibodies
analyzed in this study were produced and purified at
Amgen using standard manufacturing procedures. Wa-
ter and acetonitrile (ACN) were obtained from VWR
International (West Chester, PA, USA). Formic acid
(FA) and trifluoroacetic acid (TFA) were from Pierce
(Rockford, IL, USA). Guanidine HCl (GdnHCl) was
obtained from Mallinckrodt Baker (Phillipsburg, NJ,
USA).
Reduction and Alkylation Procedure
One IgG2 antibody used in this study was reduced and
alkylated according to the procedure described in Reh-der et al. [30]. Briefly, the antibody was diluted to 2
mg/mL using a buffer including 7.5 M GdnHCl, 0.1 M
Tris–HCl (Sigma, St. Louis, MO, USA), and 1 mM
ethylenediaminetetraacetic acid (EDTA, Sigma) at pH
7.5 to a volume of 0.5 mL. The sample was reduced with
dithiothreitol (DTT, Sigma) and alkylated with iodoace-
tic acid (IAA, Sigma). The buffer (0.5 mL) of the reduced
and alkylated protein was exchanged into 1 mL of 10
mM sodium acetate (J. T. Baker, Phillipsburg, NJ, USA)
solution at pH  5.0 to a final protein concentration of
1 mg/mL. Buffer exchange was performed using a
NAP-5 gel-filtration column packed with Sephadex
G-25 medium (Amersham Pharmacia Biotech, Orsay,
France) following the manufacturer’s recommenda-
tions. Alternatively, instead of using buffer exchange,
the reduced and alkylated sample was simply diluted
2-fold in 20 mM sodium acetate (pH  5.0) to lower the
pH and dilute guanidine-HCl to prevent its crystalliza-
tion in the autosampler at 4–8 °C.
Nano-ESI Infusion, Step Elution, and RP HPLC
Three different sample delivery systems were imple-
mented as follows. First, nano-ESI infusion was per-
formed with a solution containing 3.5 g/L of anti-
body in a ratio of 50:49:1 of acetonitrile:water:formic
acid, respectively. Second, step elution from a 10  2
mm (length  diameter) reversed-phase guard column
(Vydac C-4) was carried out using 95% acetonitrile,
0.02% TFA, and 0.08% formic acid at 0.2 mL/min.
Third, reversed-phase (RP) chromatography of intact
and reduced antibodies was performed on an Agilent
1100 Capillary HPLC system with a Zorbax SB300
300-Å pore size, 3.5-m particle size, 50  1-mm
column maintained at 75 °C, and 50 L/min flow rate.
The mobile phase was water with 0.1% (vol/vol) TFA
(solvent A) and 90% (vol/vol) n-propanol (Burdick &
Jackson, Muskegon, MI, USA), 9.9% (vol/vol) water,
and 0.1% (vol/vol) TFA (solvent B). The elution gradi-
ent was from 21 to 27% B over 20 min for intact and
from 21 to 27% over 40 min for reduced mAbs. Other
details of the RP HPLC were described elsewhere for
analysis of intact [31, 32] as well as reduced and
alkylated [30] mAbs. The column eluate was analyzed
by the on-line UV detector at 214 nm and then directed
to mass spectrometric analysis.
LTQ Orbitrap
For the analysis of intact mAbs using nano-ESI infusion,
a Thermo Scientific Nanospray I source was used
equipped with an emitter with an external conductive
coating and a 4-m-diameter tip (PicoTip, New Objec-
tive, Inc., Woburn, MA, USA). The instrument was
operated with a spray voltage of 1.4 kV, a capillary
voltage of 35 V, a capillary temperature of 250 °C, a tube
lens voltage of 220 V, an Orbitrap target value of 106,
and an Orbitrap resolving power of 15,000 (at m/z 
400). For on-line analysis after step elution and RP
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equipped with the regular Ion Max ESI/API source
(Thermo Scientific). The source was operated using
elevated voltages and temperature in the atmosphere–
vacuum interface: a capillary voltage of 140 V, a tube
lens of 250 V, a temperature of 350 °C, a sheath gas flow
of 50 units, and an auxiliary gas flow of 8 units. One
scan included three microscans with maximum injec-
tion time of 500 ms. Other Orbitrap parameters optimal
for IgG mass measurement used a resolving power of
7500 (at m/z  400), an automatic gain control (AGC)
target value of 106, and each scan including five mi-
croscans with the Fourier transform mass spectrometry
(FTMS) maximum injection time of 500 ms. The method
included one FTMS high mass range scan within m/z
1000–3500 for mass measurement and one FTMS nor-
mal mass range scan within m/z 400–2000 with source
fragmentation energy of 75 V for top-down fragmenta-
tion analysis. The fragmentation spectra were acquired
at the instrument-resolving power of 60,000 (at m/z 
400), an AGC target value of 106 and each scan includ-
ing five microscans with the FTMS maximum injection
time of 500 ms. Data acquisition for the molecular ions
and fragments was performed in profile mode. Al-
though abundant fragments were observed during in-
source collision-induced dissociation (CID) of intact
antibodies, better sequence coverage for light and
heavy chains was usually achieved when a true MS/MS
(isolation and fragmentation of parent ions in the ion
trap) was performed because of reduced interference of
an MS/MS experiment.
For analysis of heavy and light chains, the atmosphere–
vacuum interface throughput of the Ion Max ESI/API
source was optimal with the capillary at 14 V, tube lens
at 120 V and temperature at 350 °C. In-trap CID was
used because it produced better fragmentation and
sequence coverage compared with in-source dissocia-
tion. The method included one Orbitrap (FTMS) high
mass range scan (m/z 600–3000) with resolving power
of 60,000 (at m/z  400) and an AGC target value of 5 
105 followed by one MS/MS normal mass range scan
(m/z  350–2000) with the same Orbitrap resolving
power and an AGC target value of 5  105. Each scan
included five microscans with the FTMS maximum
injection time of 1500 ms. The MS/MS scan was per-
formed using an isolation width of m/z 100 around the
parent ions with m/z  990. The isolated multiply
charged ions were activated using the default CID
parameters of 30-ms activation time, a 35% normalized
collision energy, and an activation q of 0.25. All work
was conducted in the positive-ion mode.
For nano-ESI infusion and step-elution experiments,
the Orbitrap analyzer was calibrated in the high mass
range (maximum m/z value of 4000) using the calibrant
PPG2700 and sodium-TFA cluster ions, respectively.
For RP HPLC/MS studies, the Orbitrap analyzer was
calibrated in the normal mass range (maximum m/z
value of 2000) using the Ultramark calibrant. This
calibration was used for both the high mass range MSscans and normal mass range in-source and in-trap
MS/MS fragmentation scans.
Data Analysis Software
MagTran [33] and ProMass software programs were
used for deconvolution of ESI mass spectra. A program
developed at Amgen, MassAnalyzer, was used to auto-
matically assign the fragment ions [34, 35] and to
prepare the fragment coverage map [27]. It was also
used to calculate the theoretical average masses of the
antibodies and their fragments, using atomic weights of
elements from organic sources listed in reference [3].
Results and Discussion
Three different sample delivery approaches were eval-
uated for intact mAb mass measurement including
direct infusion of an off-line desalted IgG sample using
nano-electrospray (Figure 1); on-line desalting followed
by a step elution with acetonitrile from a short guard
column (Figure 2) and reversed-phase HPLC separation
of disulfide isoforms of an IgG2 antibody (Figure 3 and
Supplemental Figures S1 and S2, which can be found in
the electronic version of this article) and also reduced
antibody (Figures 4–6).
IgG Mass Measurements Using Direct Infusion
For direct infusion, the capillary voltage was set rela-
tively low (35 V) to avoid significant fragmentation of
the molecular ions. Only minor fragment ions appeared
below m/z  1700 (Figure 1a). The higher tube lens
voltage (220 V) helped transmitting the higher m/z
value ions. An Orbitrap resolving power of 15,000 gave
the optimal resolution of the glycosylation forms. Hu-
man IgG antibodies are glycoproteins containing two
identical copies of light chain (LC) and heavy chain
(HC) connected by interchain disulfide bonds (Supple-
mental Figure S2). The heavy chain has one conserved
N-glycosylation site at asparagine residue 297 (N297)
according to the Edelman numbering system. The gly-
cosylation profile typically consists of two biantennary
glycans with a variable number of terminal galactose
residues [typically from zero (G0) to four (G4), Figure
1c]. The natural variability in terminal galactose sugar
residues resulted in peaks that were 162 Da apart
(Figure 1b and c). The oligosaccharides of IgG mole-
cules do not contain (or contain only a minor percent-
age) of terminal sialic acid residues. A minor percentage
of high mannose, defucosylated and other glycoforms
of mAbs were previously reported [30, 36] and may
contribute to the background peaks in Figure 1c.
IgG Mass Measurements Using Step Elution
Step elution from a short cartridge provided conve-
nience of on-line desalting and automatic analysis of
multiple samples (Figure 2). After directing salts to
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trile through the column was stepped from 0 to 95%
and the eluting antibody molecules were ionized anddetected by the on-line Orbitrap. Sensitivity and mass
spectrometric resolution during the step elution were
better than that during the RP HPLC separation, with
slow increase of organic solvent described in the fol-
lowing text, probably because of the higher percentage
of organic solvent (95% acetonitrile) and the lower
percentage of TFA (0.02%) during the step elution,
which created more favorable electrospray conditions.
IgG1 and IgG2 antibodies typically precipitate in solu-
tions containing 40% of organic solvent and pH  3.
Therefore a low pH (pH  2.5) is required to maintain
the antibodies in solution with a high percentage of
organic solvent.
Mass Measurement and Top-Down Fragmentation
Analysis of IgG2 Disulfide Isoforms after RP
HPLC Separation
The utility of the RP HPLC/MS analysis was illustrated
by measuring masses of disulfide isoforms of an IgG2
antibody (Figure 3). Deconvoluted ESI mass spectra of
the reversed-phase peaks 1–4 of the intact monoclonal
IgG2 antibody (Figure 3c) revealed identical mass val-
ues within the 2 Da measurement error for the IgG2
disulfide isoforms, supporting previous findings [31,
37, 38]. Using nonreduced peptide mapping of collected
fractions, the peaks were previously identified as hav-
ing the same amino acid sequence and glycosylation,
but different disulfide structure at the hinge [37, 38].
The measured masses were within 2–4 Da from the
theoretical mass of 147,250 Da using atomic weights of
elements from organic sources listed in Zhang et al. [3].
As expected, formic acid instead of TFA in the
mobile phases (used in the nano-ESI and step-elution
sample delivery systems) increased the ion abundance
and mass spectrometric resolution, but decreased the
HPLC resolution of the IgG2 disulfide isoforms and the
heavy chain N-terminal forms (described in the follow-
ing text). The step-elution option is not designed to
separate the sample components chromatographically
(only to desalt them), and thus it does not require a UV
detector to quantify the components. Therefore, for
better sensitivity, it can be implemented in micro- and
nanoflow formats, for example by using the Advance
Plug and Play Nanospray source (Michrom Biore-
sources, Inc., Auburn, CA, USA). The nano-ESI sample
delivery option produced the highest intensity (per
injected g) and resolution mass spectrum because of
Figure 1. Intact IgG using nano-ESI infusion; the average of 1000
scans for 5 min of static nano-electrospray; 0.9 g was infused.
(a) ESI mass spectrum of an intact monoclonal IgG antibody with
a theoretical molecular mass of 147,250 Da for the G0 glycoform.
The Orbitrap resolving power was 15,000 at m/z 400. (b) A section
of ESI mass spectrum exhibiting multiply charged ions of intact
antibody with 54, 55, and 56 protons. (c) Deconvoluted ESI mass
spectrum of the IgG. Deconvolution was performed using Pro-
Mass software program.
610.2
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and declustering inherent to the nano-ESI process.
In addition to the accurate mass, the top-down
fragmentation information was obtained by in-source
CID within the same HPLC/MS run (Supplemental
Figure S1). Although a detailed assessment of fragmen-
tation differences for the disulfide isoforms is still under
way and will be presented in a future publication,
several general features of the top-down fragmentation
analysis should be summarized here. The fragmenta-
tion pattern of this IgG2 was similar to the fragmenta-
tion pattern of another IgG2 antibody published previ-
ously [27] and several other IgG1 and IgG2 antibodies
analyzed in the course of this study (data not shown).
The most prominent fragments were large 12-kDa frag-
ment ions containing N-terminal variable regions of the
light and heavy chains (Supplemental Figure S1), sim-
Figure 2. Intact IgG after step elution; 2 g was
after a step elution from a 2  10-mm revers
spectrum used for deconvolution. (c) Deconvo
program. The theoretical molecular mass is 149,ilar to the fragments of the other mAb described inZhang and Shah [27]. The cleavage sites for these
fragments were located in the loop between the variable
and conserved domains of light and heavy chains
shown in red in Supplemental Figure S2. Supplemental
Figure S2 shows the most complete available high-
resolution (2.7 Å, Protein Data Bank entry 1HZH)
crystal structure of an IgG1 antibody [39]. Because no
crystal structure of any IgG2 has been obtained to date,
we used this available IgG1 crystal structure to visu-
alize the cleavage sites. IgG2 and IgG1 are very
similar in primary structure and several other bio-
chemical properties, strongly suggesting similarity in
three-dimensional structure as well. Several IgG1 and
IgG2 antibodies were analyzed in this study to show
abundant fragmentation in the same conserved interdo-
main linker region shown in Supplemental Figure S1c.
It is interesting to note that fragmentation of the
ted. (a) A total-ion chromatographic peak profile
ase guard column. (b) A section of ESI mass
ESI mass spectrum using MagTran software
Da for the G0 glycoform.injec
ed-ph
lutedheavy chain was more abundant when acetonitrile was
perfo
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compared with the fragmentation during elution with
n-propanol (Supplemental Figure S1a). The same col-
umn temperature and similar mobile-phase conditions
Figure 3. Mass measurement of IgG2 disulfid
(a) Reversed-phase chromatogram with UV ab
featuring a series of MS scans (peaks) for mass
top-down analysis. (c) Deconvoluted ESI ma
monoclonal IgG2 antibody. Deconvolution was
Figure 4. RP HPLC/MS/MS analysis of heavy
IgG2 antibody, 4 g was injected. (a) The UV c
partially separated variants of the heavy chain. (
MS scans (peaks) for mass measurement and
analysis. The deconvoluted ESI mass spectra of
23,647 Da and (d) the two heavy chain variants w
of 50,893 Da and pE-HC of molecular mass of
performed using MagTran software program.were used in both cases. An even higher abundance of
heavy chain fragments was obtained when an IgG2
antibody was step-eluted with 95% acetonitrile (data
not shown). The observed difference in top-down
forms separated by RP HPLC; 4 g injected.
ance at 214 nm. (b) Total ion chromatogram
surement and in-source CID scans (valleys) for
ectra of reversed-phase peaks 1–4 of intact
rmed on MagTran.
light chains after reduction and alkylation of an
atogram of separated light chain and the two
e total ion chromatogram containing a series of
n trap CID scans (valleys) for fragmentation
he light chain with theoretical molecular mass
eoretical mass values for Q-HC molecular mass
6 Da for the G0 glycoform. Deconvolution wase iso
sorb
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b) Th
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(c) t
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difference in folding of the molecules eluting from
the column in the presence of acetonitrile and n-
propanol. The higher abundance of the heavy chain
fragments for acetonitrile suggests that eluted mole-
cules were more loosely folded and are more suscep-
tible to fragmentation in the case of acetonitrile. The
ESI charge envelope was slightly shifted to lower m/z
and higher charge states for acetonitrile, supporting
the hypothesis about the less folded and a more open
structure in acetonitrile that carries a larger number
Figure 5. The fragmentation mass spectra of (
chain. The CID of precursor ion mass m/z 990
the isolation region) was performed in the ion tr
the reduced and alkylated IgG antibody. Ions lab
most abundant fragment ions are labeled.of charges (protons).RP HPLC/MS/MS Analysis of Light and Heavy
Chains after Reduction of Disulfide Bonds
The interchain disulfide bonds between the heavy and
light chains and also intrachain disulfide bonds inside
the chains hold the structure together and suppress the
fragmentation in IgG1 (data not shown) and IgG2
antibodies analyzed in this study. As a result, the
top-down analysis of intact antibody molecules pro-
vided poor structural resolution with a relatively small
number of cleavages. After reduction and alkylation of
e heavy chain variant pE-HC and (b) the light
an isolation width m/z 100 (m/z 940–1040 as
uring automated RP HPLC/MS/MS analysis of
as a range indicate internal fragments. Only thea) th
with
ap d
eledthe disulfide bonds, HPLC/MS/MS analysis revealed
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variants and also increased the number of fragmenta-
tion sites and sequence coverage (Figures 4–6). Using
an Orbitrap resolving power of 60,000 at m/z 400,
isotopic resolution was achieved for the light chain with
an average MW 23,647 (Figure 4c). Isotopes of the heavy
chain could not be resolved at any resolving power
during our studies. The mass spectra provided useful
mass information and closely matched the calculated
masses of heavy chain sequence with N-terminal glu-
tamine (Q-HC, earlier eluting) and pyro-glutamic acid
(pE-HC, later eluting in Figure 4). N-terminal cycliza-
tion is a common modification in IgGs and requires
monitoring together with other modifications.
In-trap CID of the light and heavy chains (Figure 5)
produced a better sequence coverage compared with
that of in-source dissociation (not shown). The reason
for the better sequence coverage when applying in-trap
CIDwas likely a result of the reduced noise in the spectrum
achieved by isolating an m/z 100 range of the precursor
ions. The signal to noise was lower for the in-source
CID, when all ions from the entire m/z range were
fragmented. Monoclonal antibodies against different
antigens (targets) have different sequences and slightly
different numbers of amino acid residues in the variable
regions. Depending on the sequences of the variable
regions, the masses of heavy and light chains are
typically within 1 kDa from the average mass values of
51 and 23 kDa, respectively. The m/z 100 isolation
window fromm/z 940–1040 contained several abundant
multiply charged ions of light chain (typically 23,
24, 25) and heavy chain (typically from 49 to 54).
Figure 6. Amino acid sequence and fragment c
chain of the reduced and alkylated IgG2 antibo
induced dissociation mass spectra in Figure 5
conserved regions are provided. The letters “X” i
only to this IgG2.Selection of a large isolation width (m/z 940–1040) wasan attractive option because it provided a universal
fragmentation parameter for light and heavy chains of
different mAbs (against different antigens) with differ-
ent masses. This enabled an automated analysis of
different IgG molecules without a prior knowledge of
their masses. Using the maximal allowed isolation
width of m/z 100, it was possible to reliably isolate and
perform an automated MS/MS analysis of chains from
any monoclonal IgG antibody. Using a large isolation
width, however, calls for complete chromatographic
separation of isoforms. For those experiments where
complete chromatographic separation could not be
achieved, an isoform of interest was isolated with a
width of m/z 10 (data not shown), similar to the proce-
dure described by Macek et al. [22]. This approach of
using a narrow isolation window has an advantage,
because it minimizes the need for chromatographic
separation of protein variants. On the other hand, it
requires a prior knowledge of the mass of protein
isoform of interest, which is not practical for an auto-
mated high-throughput analysis of different antibodies.
The fragmentation spectrum of the heavy-chain vari-
ant with N-terminal glutamine (Q-HC, not shown here)
was similar to the fragmentation mass spectrum of the
heavy chain with N-terminal pyro-glutamate (pE-HC,
Figure 5a). All b-fragment ions of Q-HC were 17 Da
heavier, pointing to the difference between the two
heavy chain variants is on the N-terminus. These find-
ings unambiguously indicated that these two variants
were attributed to the N-terminal cyclization. In addi-
tion to the b-fragment ions containing N-terminal glu-
tamine, the fragmentation mass spectrum of the earlier
ge maps of (a) the heavy chain and (b) the light
enerated by MassAnalyzer using the collision-
d b. Only the sequences for the frames and
te complementarity determining regions uniqueovera
dy g
a an
ndicaeluting variant also contained abundant (b-17) Da frag-
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these peaks. They could be attributed to the incomplete
separation of Q-HC and pE-HC or to the susceptibility
of N-terminal glutamine to ammonia loss during frag-
mentation in the gas phase [30]. The chromatographic
peaks for the heavy and light chains provided useful
fragmentation coverage (Figure 6), which can be poten-
tially used in other applications to identify sites of
modifications, even if they are located in the middle of
the chains. The majority of the fragments were repre-
sented by two or more charged forms (Figure 5). All
fragment assignments shown here were automatically
generated by MassAnalyzer software (using typically
an 8 ppm mass accuracy threshold) and then validated
manually by comparing their experimental isotope pat-
tern to the calculated (by MassAnalyzer) theoretical
isotope pattern.
Conclusions
Average masses of several 150-kDa intact monoclonal
IgG antibody molecules were accurately determined
using an Orbitrap analyzer within 2 Da using the
following delivery methods: (1) nano-ESI infusion, (2)
step-elution, and (3) on-line reversed-phase HPLC. For
online HPLC/MS analysis, both accurate mass and
top-down fragmentation data were acquired within a
short 20-min reversed-phase HPLC/MS run, using the
Orbitrap analyzer alternating between a high mass
range scan (for intact protein mass measurement) and a
normal mass range scan with in-source fragmentation
(for top-down analysis). The method can be used in
pharmaceutical applications to establish identity and
assess chemical modifications and mutations of thera-
peutic monoclonal IgG antibodies. The utility was illus-
trated by characterizing disulfide isoforms of an IgG2
antibody (Figure 3 and Supplemental Figures S1 and
S2) and glutamine and pyro-glutamate variants of a
heavy chain (Figures 4–6). The glycosylation profile,
including several glycoforms with different numbers of
terminal galactose residues (n  162 Da), were deter-
mined from mass spectra of intact and reduced IgG
antibodies. The use of acetonitrile instead of n-propanol
in the mobile-phase increased abundance of heavy-chain
top-down fragments, but decreased HPLC resolution.
An initial evaluation indicated that HPLC/MS/MS
of light and heavy chains of a reduced and alkylated
IgG increased the number of fragmentation sites and
structural resolution of analysis (Figures 4–6), com-
pared with the top-down analysis of intact IgG. This
“middle-down” method was further developed and
previously described [40]. Isotopic resolution of the
light chain with an approximate MW 23 kDa during
on-line RP HPLC/MS analysis was achieved. Although
isotopes for the heavy chain (MW 51 kDa) and intact
antibody (MW 150 kDa) were unresolved at this time,
we are looking forward to resolving them on new
generations of Orbitrap analyzers. A future direction is
aimed at obtaining more complete structural coverage(cleavage at every residue), which should be possible
with additional dissociation methods and further devel-
opment of Orbitrap technology.
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